Interleukin 12/23 agents and major adverse cardiovascular events

Archives of Dermatology

Volumn 148, Issue 11, 2012, Pages 1329-

  Lebwohl, Mark ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 23 ANTIBODY; PLACEBO; USTEKINUMAB;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CROHN DISEASE; DRUG USE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; NOTE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS;

ANTIBODIES, MONOCLONAL; CARDIOVASCULAR DISEASES; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MYOCARDIAL INFARCTION; PSORIASIS; STROKE;

EID: 84869813921     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/2013.jamadermatol.88     Document Type: Note

References (6)

1. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306(8):864-871.
2. Bigby M. The use of anti-interleukin-12/23 agents and major adverse cardiovascular events. Arch Dermatol. 2012;148(6):753-754.
3. Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol. 2011;164(4):862-872.
4. Sandborn WJ, Gasink C, Long-Long G, et al. A multicenter, randomized, double-blind, placebo-controlled phase 2b study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately to severely active Crohn's disease: results through week 22 from the CERTIFI Trial [abstract 592]. Gastroenterology. 2011;140(suppl 1):S-109.
5. Tsai TF, Ho JC, Song M, et al PEARL Investigators. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63(3):154-163.
6. Zheng M, Zhu X, Song M, Shen Y-K, Wang B. A randomized, double-blind, placebo-controlled study of ustekinumab in Chinese patients with moderate to severe plaque psoriasis: LOTUS trial results. Presented at the World Psoriasis and Psoriatic Arthritis 2012 Conference; June 27 to July 1, 2012; Stockholm, Sweden.